Turin, Piedmont, Italy
Sibylla Biotech: 09/2025 Head of Pharmacology Responsible for overseeing and managing all in vivo studies conducted by the company, ensuring scientific rigor, compliance with regulatory standards. Managing collaborations with external CRO, working across the MedChem team, the Biology team and the Compound Management to ensure the smooth progression of PK, PK/PD, and Efficacy studies. Preparing comprehensive reports for investors and external communications Sibylla Biotech: 09/2023 onwards Principal Scientist for Translational Research at Sibylla Biotech. Novartis: 2021-04/2023: As a member of the Preclinical Oncology group at the Novartis Institute for Biomedical Research (NIBR), Radio Ligand Therapy (RLT) and Radio Ligand Imaging (RLI). My role involves overseeing a range of tasks, including closely collaborating with external Contract Research Organizations (CROs) as a Preclinical Study Monitor. I also provide scientific insights to support the Medical Advisory Board in planning and executing clinical studies. Additionally, I produce Competitive Intelligence reports and assess external assets to inform strategic decision-making. University of Oxford: 10/2017-05/2021 As a postdoctoral researcher at the Platform Precision Panc UK, my work was focused on investigating how radiotherapy and the modulation of the tumor microenvironment, (tumor-associated macrophages, T-regs, and immune checkpoints) influenced pancreatic tumor progression. We combined MRI-guided radiotherapy and immune checkpoint inhibitors in an orthotopic mouse model to "re-educate" the tumor microenvironment and the immune system. I was responsible for setting up all preclinical trials in our lab, and we studied the immune system's response to treatments using immunohistochemistry and flow cytometry. 06/2015-10/2017 . As a Research Associate at the European Cancer Stem Cell Research Institute, I worked on the "Development of Novel CD200:CD200R Blockade Cancer Immunotherapy" project. 11/2011 – 10/2014 PhD student in Clinical and Experimental Medicine working in the Laboratory of Molecular Virology, Department of Translational Medicine, Medical School of Novara, Italy (Head: Prof. Marisa Gariglio). 03/2009 – 03/2011. Student in Veterinary Biotechnologies working on the project “Small Ruminant Lentivirus (genotype E) viral load and tissue distribution study” at the Laboratory of Infectious Disease, Animal Product Department, Veterinary Medicine, University of Turin.
I'm responsible for all the preclinical in vivo activity for Sibylla Biotech, driving our science and translating our PPI-FIT technology in to, one day, a clinically approved drug. To know more about our mission and our work come and have a look at Sibylla Biotech #FoldTheFuture
My focus is in the field of Nuclear Medicine, specifically in the Preclinical Radio Ligand Therapy (RLT) and Radio Ligand Imaging (RLI) Oncology group at Novartis Institute for Biomedical Research (NIBR). In this role, I provide scientific support for several clinical studies and produce Competitive Intelligence reports and external assets evaluations. Additionally, I work as a Preclinical Study Monitor, collaborating closely with external CROs to conduct preclinical studies. I provide the scientific background to support several clinical studies, I produce Competitive Intelligence reports and external assets evaluation. I work on preclinical studies as Study Monitor in close contact with external CROs.
My work focused on investigating how the combination of radiotherapy and immune therapies could impact pancreatic tumor progression. I combined MRI-guided radiotherapy with various immunotherapies (including PD1/PD-L1, CTLA4, CXCR2, CSF1R, and CD40) to "re-educate" the immune system in its response to the tumor.